聚乙二醇干扰素α-话题@MedSci - 梅斯（MedSci）

#聚乙二醇干扰素α#

3篇内容 | 1687人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2196046, encodeId=ab2b219604661, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a> <a href='/topic/show?id=f4b511289e51' target=_blank style='color:#2F92EE;'>#AASLD2023#</a>, objectTitle=【AASLD2023速递】治疗应答探索：差异表达基因或会影响慢乙肝患者对聚乙二醇干扰素α的应答, objectType=article, longId=818249, objectId=bc1d818249ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=bc1d818249ff, replyNumber=0, likeNumber=79, createdTime=2024-03-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=bc1d818249ff, moduleTitle=【AASLD2023速递】治疗应答探索：差异表达基因或会影响慢乙肝患者对聚乙二醇干扰素α的应答, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bc1d818249ff)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195713, encodeId=ff4b2195e1313, content=<a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a> <a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a> <a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, objectTitle=【期刊导读】首个荟萃分析：聚乙二醇干扰素α治疗慢性HBV感染患者获得HBsAg清除的预测因素, objectType=article, longId=818046, objectId=1507818046bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=1507818046bd, replyNumber=0, likeNumber=69, createdTime=2024-03-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1507818046bd, moduleTitle=【期刊导读】首个荟萃分析：聚乙二醇干扰素α治疗慢性HBV感染患者获得HBsAg清除的预测因素, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1507818046bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193600, encodeId=b7582193600eb, content=<a href='/topic/show?id=7056112354a6' target=_blank style='color:#2F92EE;'>#亚太肝脏研究协会年会#</a> <a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a> <a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a> <a href='/topic/show?id=cb65813029a' target=_blank style='color:#2F92EE;'>#肝硬化#</a>, objectTitle=【APASL2024速递】HBeAg阳性代偿期肝硬化患者使用聚乙二醇干扰素α-2b治疗的疗效更优, objectType=article, longId=817082, objectId=7a5381e082fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=7a5381e082fc, replyNumber=0, likeNumber=127, createdTime=2024-03-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7a5381e082fc, moduleTitle=【APASL2024速递】HBeAg阳性代偿期肝硬化患者使用聚乙二醇干扰素α-2b治疗的疗效更优, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7a5381e082fc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193233, encodeId=34062193233bd, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a> <a href='/topic/show?id=b15911228473' target=_blank style='color:#2F92EE;'>#胸腺肽α1#</a> <a href='/topic/show?id=8d911122850b' target=_blank style='color:#2F92EE;'>#HBsAg血清学#</a>, objectTitle=【临床治愈集结号】核苷经治慢乙肝患者联合聚乙二醇干扰素α和胸腺肽α1治疗获HBsAg血清学转换且cccDNA清除, objectType=article, longId=817090, objectId=bd9b81e09011, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=bd9b81e09011, replyNumber=0, likeNumber=157, createdTime=2024-03-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bd9b81e09011, moduleTitle=【临床治愈集结号】核苷经治慢乙肝患者联合聚乙二醇干扰素α和胸腺肽α1治疗获HBsAg血清学转换且cccDNA清除, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bd9b81e09011)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192285, encodeId=a368219228554, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a> <a href='/topic/show?id=d133112103aa' target=_blank style='color:#2F92EE;'>#低病毒血症#</a> <a href='/topic/show?id=a8952625e5' target=_blank style='color:#2F92EE;'>#APASL#</a>, objectTitle=【APASL2024速递】新证据汇总：慢乙肝低病毒血症患者联合聚乙二醇干扰素α治疗可在多方面获益, objectType=article, longId=816220, objectId=dd718162207c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-team-discussing-together-in-the-hallway-PJWSSDB.jpg, objectUrl=/article/show_article.do?id=dd718162207c, replyNumber=0, likeNumber=93, createdTime=2024-03-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dd718162207c, moduleTitle=【APASL2024速递】新证据汇总：慢乙肝低病毒血症患者联合聚乙二醇干扰素α治疗可在多方面获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dd718162207c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190754, encodeId=ecf32190e5463, content=<a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a> <a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a>, objectTitle=【期刊导读】慢乙肝患者生活质量和病毒学应答：接受聚乙二醇干扰素α治疗的显著更高, objectType=article, longId=815456, objectId=1119815456d3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=1119815456d3, replyNumber=0, likeNumber=93, createdTime=2024-03-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1119815456d3, moduleTitle=【期刊导读】慢乙肝患者生活质量和病毒学应答：接受聚乙二醇干扰素α治疗的显著更高, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1119815456d3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1934197, encodeId=6efb193419e02, content=<a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a>, objectTitle=聚乙二醇干扰素α治疗慢性乙型肝炎专家共识, objectType=article, longId=119062, objectId=6d19119062dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d19119062dd, replyNumber=0, likeNumber=96, createdTime=2017-11-11, rootId=0, userName=weiz, userId=1c77441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d19119062dd, moduleTitle=聚乙二醇干扰素α治疗慢性乙型肝炎专家共识, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d19119062dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934196, encodeId=523119341968d, content=<a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a>, objectTitle=Gastroenterology：MK-5172、聚乙二醇干扰素α-2a和病毒唑联合给药对首次接受治疗的慢性丙肝患者有效, objectType=article, longId=42340, objectId=325142340b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=325142340b2, replyNumber=0, likeNumber=78, createdTime=2015-03-05, rootId=0, userName=weiz, userId=1c77441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=325142340b2, moduleTitle=Gastroenterology：MK-5172、聚乙二醇干扰素α-2a和病毒唑联合给药对首次接受治疗的慢性丙肝患者有效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=325142340b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934195, encodeId=3e4d193419565, content=<a href='/topic/show?id=c59480e81c7' target=_blank style='color:#2F92EE;'>#聚乙二醇干扰素α#</a>, objectTitle=NEJM:伊马替尼加聚乙二醇干扰素α-2a 在慢性髓系白血病中的疗效, objectType=article, longId=2323, objectId=540623233e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=540623233e, replyNumber=0, likeNumber=115, createdTime=2011-02-19, rootId=0, userName=weiz, userId=1c77441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=540623233e, moduleTitle=NEJM:伊马替尼加聚乙二醇干扰素α-2a 在慢性髓系白血病中的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=540623233e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

聚乙二醇干扰素α

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #聚乙二醇干扰素α# #AASLD2023#

【AASLD2023速递】治疗应答探索：差异表达基因或会影响慢乙肝患者对聚乙二醇干扰素α的应答

2024-03-29发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#聚乙二醇干扰素α# #HBV# #HBsAg#

【期刊导读】首个荟萃分析：聚乙二醇干扰素α治疗慢性HBV感染患者获得HBsAg清除的预测因素

2024-03-27发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#亚太肝脏研究协会年会# #APASL# #聚乙二醇干扰素α# #肝硬化#

【APASL2024速递】HBeAg阳性代偿期肝硬化患者使用聚乙二醇干扰素α-2b治疗的疗效更优

2024-03-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #聚乙二醇干扰素α# #胸腺肽α1# #HBsAg血清学#

【临床治愈集结号】核苷经治慢乙肝患者联合聚乙二醇干扰素α和胸腺肽α1治疗获HBsAg血清学转换且cccDNA清除

2024-03-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #聚乙二醇干扰素α# #低病毒血症# #APASL#

【APASL2024速递】新证据汇总：慢乙肝低病毒血症患者联合聚乙二醇干扰素α治疗可在多方面获益

2024-03-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#聚乙二醇干扰素α# #慢乙肝#

【期刊导读】慢乙肝患者生活质量和病毒学应答：接受聚乙二醇干扰素α治疗的显著更高

2024-03-03发表于上海

weiz (审核中...)

前往app查看评论内容

#聚乙二醇干扰素α#

聚乙二醇干扰素α治疗慢性乙型肝炎专家共识

2017-11-11

weiz (审核中...)

前往app查看评论内容

#聚乙二醇干扰素α#

Gastroenterology：MK-5172、聚乙二醇干扰素α-2a和病毒唑联合给药对首次接受治疗的慢性丙肝患者有效

2015-03-05

weiz (审核中...)

前往app查看评论内容

#聚乙二醇干扰素α#

NEJM:伊马替尼加聚乙二醇干扰素α-2a 在慢性髓系白血病中的疗效

2011-02-19

科室
- - 订阅+
  - 更多科室
工具
服务